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Abstract
Background: Recently, we established that a C.T single nucleotide polymorphism (SNP) in the promoter of the VEGF
receptor FLT1 gene generates a K site p53 response element (RE-T) that results in p53 responsiveness of the promoter. The
transcriptional control required an estrogen receptor (ER) K site response element (ERE1) 225 nt upstream to the RE-T.
Methodology/Principal Findings: Here we report the identification of a second ER K site (ERE2) located 145 bp
downstream of the RE-T and establish that both EREs can impact p53-mediated transactivation of FLT1-T in a manner that is
cell type and ER level dependent. Gene reporter assays and ChIP experiments conducted in the breast cancer-derived MCF7
cells revealed that the ERE2 site was sufficient for p53-mediated ERa recruitment and transactivation of the FLT1-T
promoter/reporter construct. Surprisingly, unlike the case for other p53 target promoters, p53-mediated transactivation of
FLT1-T constructs or expression of the endogenous FLT1 gene, as well as binding of p53 and ER at the promoter constructs,
was inducible by doxorubicin but not by 5-fluorouracil. Furthermore, ER activity at FLT1-T was differentially affected by ER
ligands, compared to a control TFF1/pS2 ER target promoter. The p53-related transcription factors (TFs) p73 and p63 had no
effect on FLT1 transactivation.
Conclusions/Significance: We establish a new dimension to the p53 master regulatory network where p53-mediated
transcription from a K site RE can be determined by ER binding at one or more cis-acting EREs in manner that is dependent
on level of ER protein, the type of ER ligand and the specific p53-inducing agent.
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Introduction
The Vascular Endothelial Growth Factor Receptor-1 (VEGFR-
1), commonly known as FLT1, is a high affinity VEGF receptor
belonging to the VEGFR transmembrane receptor tyrosin kinase
family, expressed in a variety of cell types, including endothelial
cells, hematopoietic stem cells, leucocytes, and osteoblasts [1]. The
FLT1 protein, which possesses higher affinity for VEGFA but
weak tyrosine kinase activity, or none at all in the case of the
soluble form (sFLT1), can act as inhibitory or decoy [2] to the
FLK1/VEGFR-2 receptor. The latter binds to VEGFA and
represents a primary driver of angiogenesis in development and
healthy conditions. Phenotypes from animal models are consistent
with a negative modulation of vasculogenesis/angiogenesis by
FLT1 during development [3]. However, FLT1 can positively
regulate angiogenesis in the context of various stress responses and
diseases, including cancer. Unlike FLK1, the FLT1 gene can be
up-regulated by hypoxia due to the presence of an HIF-1a binding
site in the promoter [4]. Moreover, only FLT1can bind to VEGFB
and Placental Growth Factor (PlGF) ligands that are overex-
pressed in pathological conditions and result in activation of
intracellular signals [3,5]. The efficiency of signal transduction via
FLT1 and upon binding to specific ligands can also be enhanced
by the cell surface coreceptors neuropilin [6], that in addition to
binding the semaphorins during neuronal development can also
bind selected VEGF subtypes.
Consistent with a role in pathological angiogenesis, FLT1 can
be up-regulated in several tumor types, including prostate, breast,
colon and non-small cell lung cancer, lung adenocarcinoma,
hepatocellular carcinoma and glioblastoma [7–12]. Notably,
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[13–15]. FLT1 is also important in tissue-specific metastasis, since
bone marrow-derived hematopoietic progenitor cells that express
FLT1 appear to be required for the formation of the ‘‘pre-
metastatic niche’’ [16].
Recently, we established that expression from the FLT1
promoter could be modulated in response to genotoxic stress by
concomitant activation of the p53 tumor suppressor and Estrogen
Receptors (ERs) [17]. Modest p53-dependent responsiveness of
the promoter was related to the presence of a single nucleotide
polymorphism (SNP) in the proximal FLT1 promoter [18]. The
relatively rare C.T allele results in a K site p53 response element
(RE) that is necessary but not sufficient for a substantial p53-
dependent transcriptional effect. Subsequent investigations showed
that ligand-activated Estrogen Receptor acting at a K site
Estrogen Receptor response element (ERE) located upstream of
the p53 RE was required for high level of p53-dependent
responsiveness [17].
The master regulator and tumor suppressor p53, which is one
of the most important and studied proteins in the cancer field, is a
tetrameric (dimer of dimer proteins) sequence-specific transcrip-
tion factor able to bind to two copies of a decameric sequence
with the RRRCWWGYYY consensus (where R stands for a
purine, W for A/T and Y for a pyrimidine) [19]. Recent results,
including our own investigation based on functional or DNA
binding assays in cell systems or cell extracts, established that
maximal transactivation requires adjacent dimer binding sites
[20–26]. A spacer of a few bases dramatically reduced
transactivation. We also established that p53 can stimulate
transcription, albeit at a reduced levels, from noncanonical
response elements including K sites [26] (reviewed in [27]).
Deviations from consensus are common among established p53
target sites resulting in a wide range of transactivation potentials.
The same sequence-specific requirements that were shown to
maximize the transactivation potential from full site REs appear
to be valid for the K site REs [26]. The C.T SNP in the FLT1
promoter changes a critical mismatch in a p53 K site that
prevents function into a consensus sequence that provides for
weak p53 transactivation [17].
The ERs belong to a large superfamily of nuclear receptor
transcription factors that interact with specific ligands to regulate a
variety of cellular pathways [28]. The ligand-induced conforma-
tional change enables ER to modulate transcription from EREs
directly and through recruitment of cofactors. The ERE consensus
sequence comprises two inverted repeats of the GGTCA
pentamer, although EREs often contain nonconsensus bases
[29–31]. The repeats are typically separated by a 3 nt-based
spacer [32,33]. Many ligands can interact with ER proteins and
can impact differentially the transactivation at specific EREs.
Acting in cooperation with other transcription factors such as Sp1
[34], ERs can also modulate transcription from K site EREs.
Our previous results with the FLT1 promoter established
transcriptional cooperation between p53 and ER. The noncano-
nical nature of the cognate response elements present in the
promoter enabled strong responsiveness only upon concomitant
activation of both transcription factors. In this study these findings
have been expanded to an ER positive, p53 wt breast cancer-
derived cell model in order to better understand the cooperative
relationship between ER and p53 in cis-regulation of FLT1
expression. We found that ER levels, specific ligands and
genotoxic stresses can greatly influence the coordinated regulation
of expression of the FLT1-T allele. In a more general sense, these
findings indicate that a noncanonical p53 RE can provide a wide
opportunity for fine-tuning p53-dependent cellular responses and
for integrating signaling-responses to complex environmental
perturbations.
Results
An additional ERE K site contributes to p53/ER
responsiveness of the FLT1-T promoter
We previously established that in addition to the K site p53 RE
(2677 from the Transcriptional Start Site, TSS) a K site ERE
located 225 nt upstream of the p53 RE (referred to as ERE1;
2902 from TSS) is required for efficient p53-induced transactiva-
tion of the FLT1 promoter [17]. The cooperative interaction was
mainly studied in the colon adenocarcinoma HCT116 cell line
that expresses wild-type p53 protein (referred to as p53
+/+). This
cell line is ERa negative and weakly expresses ERb.T o
understand better the cooperativity between p53 and ERs in the
regulation of FLT1 promoter and the response to genotoxic stress,
we evaluated the role of ERs in the p53-dependent transactivation
of the FLT1 using a clone of the p53 wild-type breast
adenocarcinoma MCF7 cell line which is positive for ERa and
has low ERb expression. Surprisingly, while in HCT116 cells the
disruption of the 2902 ERE K site (i.e., ‘‘ere1’’) was sufficient to
nearly abolish the transactivation from a 1 kb FLT1-T promoter
construct [17], there was no impact of the disruption in MCF7
cells (Figure 1A). The FLT1-C promoter construct was equivalent
to the empty vector.
To investigate the cell-specific impact, we first performed
in silico analyses of the FLT1 promoter for transcription factor
binding sites using the Genomatix MatInspector [35] as well
as Transcription Element Search System (TESS) software
(MatInspector: http://www.genomatix.de/products/MatInspector;
TESS: University of Pennsylvania Computational Biology and
Informatics Biology Laboratory, http://www.cbil.upenn.edu/tess).
This led to the identification of a second putative ERE K site
(ERE2: GGTCAggagcggC; mismatched based from a consensus
full site ERE are underlined) located 145 nt downstream to the p53
RE (Figure 1B). To evaluate the contribution of ERE2 in the p53,
ER mediated transactivation we developed luciferase-based
reporter plasmids containing 1 kb FLT1-T promoter constructs
harboring inactivating mutations at either of the ERE sites (‘‘ere1’’
or ‘‘ere2’’) as well as a double mutant (‘‘ere1,2’’) (described in details
in Figure 1B). Gene reporter assays clearly showed that in MCF7
cells both EREs needed to be inactivated to impair p53-dependent
transactivation (Figure 1A).
Next we asked whether the relative activity for ERE1 is strictly
dependent on the K site context (GGTCA) or could be affected by
the adjacent sequence 39 to it (GGTCAgagTcACt) which, unlike
the case of ERE2, contains some features of an ERE K site in
opposite orientation and correctly spaced from ERE1 although
there are mismatches at two critical positions (lowercase) [30,36].
We constructed a ‘‘pure’’ ERE1 K site by site-directed
mutagenesis (referred to as ‘‘puERE’’, where the remaining
consensus ERE bases were changed -TcACtt oT cctt- see Table
S1 and Figure 1B). This modification did not impact the induction
of transactivation in MCF7 cells (Figure 1A).
We then addressed whether the difference in responsiveness
seen between HCT116 [17] and MCF7 could be related to
intracellular levels of ER proteins. Ectopic overexpression of either
ERa or ERb in HCT116 along with the various FLT1-T
constructs and doxorubicin treatment resulted in all but the
ere1,2 double mutant being responsive (Figure 1C and 1D). ERb
overexpression resulted in higher relative transactivation of
FLT1-T in response to doxorubicin treatment, suggesting an
important role for this receptor in the cooperation with p53.
FLT1 Cis-Regulation by p53&ER
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associated with the individual ere1 and ere2 constructs was still
apparent upon ectopic expression of ERb. Notably, disruption of
ERE2 alone did not completely abolish the responsiveness to
doxorubicin even without ER ectopic expression, possibly related
to the difference in sequence between ERE1 and ERE2 and their
relative closeness to the ER consensus. Consistent with this, the
responsiveness to doxorubicin of the puERE construct was
significantly lower compared to FLT1-T in HCT116 cells (not
shown). Surprisingly, the empty vector was inducible by
doxorubicin when the ERs were overexpressed in HCT116 cells
(especially with ERb). An even higher induction of the empty
vector by doxorubicin was observed in MCF7 cells (Figure 1A).
This might in part be due to the presence in close proximity of
both a p53 RE and an ERE in the pGL3 promoter plasmid as
predicted by the Gemomatix MathInspector (not shown) and
could thus be influenced by the expression of p53 and ER
proteins. The p53-dependence of the doxorubicin treatment on
transactivation of the FLT1-T constructs was confirmed with a
p53-null HCT116-derived cell line (Figure 1E). In the absence of
p53, the overexpression of either ERa or ERb did not lead to any
further differential stimulation of the FLT1 reporter constructs
although a higher basal level with just the plasmid backbone was
observed independent from the SNP status or the ERE sequences
(Figure 1E). Doxorubicin treatment resulted in p53 protein
stabilization in both p53 positive cell lines and was not affected by
transfection with the reporter constructs (Figure 1F). Unlike the
FLT1-T reporter, the pS2/TFF1 ER reporter construct was
highly inducible by overexpressed ERa or ERb in HCT116
p53
2/2 cells, confirming the activity of the ER proteins in our
culture conditions (Figure 1G). The relative impact of disrupting
the ERE1 or ERE2 sites was evaluated in MCF7 cells also in
estrogen-reduced culture conditions supplemented with 10 nM
estradiol and treated or not with doxorubicin (Figure 1H).
Interestingly, in these conditions only the disruption of one ERE
was sufficient to bring the doxorubicin responsiveness down to
the level of the empty vector. While the results confirmed
that ERE2 is a functional ERE, they also highlighted the
strong influence of the experimental conditions in the FLT1
cis-regulation.
The transcriptional cooperation between p53 and ERs was also
examined in human endothelial cells derived from dermal
microvessels (HMEC) using ectopic expression conditions
(Figure 2). While the FLT1-C construct was not responsive to
p53 and/or ERs, transcriptional cooperation was observed with
the FLT1-T, particularly when both ERa and ERb were
overexpressed together with p53. Consistent with the results in
MCF7 and in HCT116 p53
+/+ cells, the FLT1-T-ere1 construct
was also inducible by ectopic expression of p53, especially when
ERa and ERb were also expressed ectopically.
Neither p63 nor p73 can modulate transactivation of the
FLT1 promoter construct
Since the p53-related transcription factors p63 and p73 can
modulate p53 functions and activate the transcription of some p53
target genes [37,38], we examined the impact at the FLT1
promoter alleles using gene reporter assays and ectopic expression
of p53 or of selected p63 and p73 isoforms. We also evaluated the
effect of doxorubicin treatment along with the ectopic over-
expression.
These experiments were conducted in SaOS2 cells which lack
endogenous p53. Ectopic p53 expression resulted in modest
transactivation of FLT1-T, consistent with the small amount of
p53 expression plasmid that was used for transfections (100 ng/
well). While in previous experiments more p53 plasmid was used
(500 ng/well) [18], we chose conditions in which the impact of
doxorubicin along with ectopic p53 expression could be assessed.
In the absence of p53 the FLT1 promoter constructs exhibited low
level transactivation similar to the empty vector (Figure 3A). The
treatment with doxorubicin led to a small induction (,1.5 fold).
The ectopic expression of p53 resulted in a weak stimulation for all
reporter constructs (2.0, 2.6 and 2.3 fold, respectively, for empty
vector, FLT-C and FLT1-T). The promoter context had an
impact in p53-expressing cells, as FLT1-T but not FLT1-C
resulted in significantly higher activity compared to the empty
vector (1.6 vs 1.2 fold induction). Doxorubicin treatment in p53-
expressing cells led to slightly higher transactivation of the FLT1-C
reporter (1.3 fold) and greater transactivation of FLT1-T (2.1 fold).
The impact of the SNP on the combination of ectopic p53
expression and doxorubicin treatment was highly significant. The
PG13 reporter plasmid, a canonical p53 responsive construct,
containing a tandem repeat of a p53 RE [39], exhibited high
responsiveness to the ectopic expression of p53 that was further
stimulated by the doxorubicin treatment (Figure 3B). Ectopic
expression of the p53-related transcription factors p73b or p63c
(corresponding to the spliced isoforms that are transcriptionally
more active) failed to modulate the response from the FLT1
promoter, regardless of SNP status, although the PG13 control
reporter was induced by both proteins.
Differential impact of doxorubicin and 5-fluorouracil on
p53-dependent FLT1-T transactivation
Next we examined whether the nature of the genotoxic stress
that leads to p53 stabilization and activation could impact FLT1-T
transactivation using MCF7 cells. Interestingly, the thymidylate
Figure 1. Two distinct ER K site response elements acting in cis along with estrogen receptors contribute to doxorubicin-induced,
p53-dependent transactivation of the FLT1-T promoter. (A) MCF7 cells cultured in normal medium. (C & D). HCT116 p53
+/+ cells. Gene
reporter assays results are presented as the average light units and the standard errors of three independent biological replicates. The indicated
reporter plasmids were transiently transfected along with the pRL-SV40 control vector. When indicated, the HCT116 p53
+/+ cells were treated with
doxorubicin (Doxo ‘‘+’’ ) at 0.3 mg/ml for 16 hours prior to cell lysis. Luciferase activity was measured 48 hours post-transfection and normalized for
transfection efficiency. Statistically significant differences are highlighted (*= p,0.01; ‘=p,0.05, t-test). (B) Partial sequence of the 1 kb FLT1
proximal promoter. The ERE1, p53 RE and ERE2 sequences are highlighted (uppercase: bases matching the consensus sequences) and their relative
position with respect to the Transcriptional Start Site (1) is shown. Also presented is a schematic drawing of the reporter constructs based in the pGL3
promoter vector containing a 1 Kb fragment of the FLT1 promoter. The specific mutations introduced to inactivate the ERE1 and ERE2 sites are
indicated (bold lowercase). (C,D) Cells were transiently co-transfected with the empty pGL3 vector or the indicated reporter constructs along with an
expression vector leading to overexpression of ERa (C) or ERb (D). (E) HCT116 p53
2/2 cells were used as a control for the p53-dependence of the
combined effect of doxorubicin treatment and ERa or ERb expression on the transactivation of the FLT1 promoter constructs. (F) Representative
western blot showing the increase in p53 protein levels after doxorubicin treatment; b-actin was used as loading control. For each cell line, p53
protein levels were assessed in a duplicate experiment to confirm that the transfection with different reporter plasmids did not impact p53
stabilization. (G) HCT116 p53
2/2 cells were transfected with the pS2/TFF1 ER reporter along with empty or overexpression vectors for ERa or ERb.H .
MCF7 cells cultured in estrogen-depleted media supplemented with 10 nM E2.
doi:10.1371/journal.pone.0010236.g001
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agent commonly used to study p53-mediated responses [40–42]
did not result in transactivation of the FLT1-T construct, although
p53 protein levels as well as p21 were increased comparably by
doxorubicin and 5FU with respect to mock treated cells (Figure 4A
and 4B). In addition, 5FU treatment did not considerably affect
the expression levels of ERa protein (Figure 4B), nor its activity,
based on gene reporter assays conducted in estrogen-depleted
medium supplemented with 100 nM E2 (Figure 4C). Further-
more, as described below, the endogenous FLT1 gene expression
was inducible by doxorubicin but not 5FU.
Differential impact of doxorubicin and 5FU treatment on
the recruitment of p53 at the RE-T and the role of ERE1
and ERE2
We previously demonstrated using HCT116 p53
+/+ and p53-
transfected SaOS2 cells that the ERa or ERb could bind only the
FLT1-T promoter construct in the presence of p53 suggesting that
p53 binding was required for ER binding [17]. These findings
have been extended to the impact of ERE1 and of the double
ERE1, ERE2 mutations on occupancy at EREs and p53 REs
using MCF7 cells transfected with the various FLT1 promoter
constructs. Specific primers for amplifying the ERE1, ERE2 and
the p53 RE sites on plasmid reporters were developed (Figure 5A
and Table S2), as well as sonication conditions that enabled us to
evaluate the distinct contribution of ERE1 and ERE2. The impact
of doxorubicin and 5FU treatments were also compared (Figure 5).
First we tested the ability of p53 and ERa to be recruited to a
canonical target promoter site (p21 and TFF1, respectively). The
different DNA damaging agents resulted in enhanced p53
occupancy at the p21 promoter, consistent with other reports in
the literature [43], while those same treatments appeared to
similarly reduce ER occupancy at the pS2 control target (Figure
S1A and S1B). While doxorubicin-treatment led to a significant
increase in p53 occupancy levels at the p53 RE-T within the FLT1
promoter fragment, treatment with 5FU did not induce p53
occupancy at the site, consistent with the failure of the 5FU-
dependent FLT1-T transactivation (Figure 5B & 5C). Doxorubicin
treatment also resulted in ERa occupancy detectable with the
primers both for the ERE1 and ERE2 sites (Figure 5B, top panel;
5C, left panel). Inactivation of the ERE1 site did not affect p53
occupancy, but the inactivation of both ERE1 and ERE2 greatly
reduced p53 occupancy, consistent with a cooperative cis
interaction between p53 and ER (Figure 5B, lower panel; 5C
center and right panel). Mutation of the ERE1 site abolished ERa
recruitment at the site, but doxorubicin-enhanced occupancy was
still detectable at the ERE2 site. The double ere1,2 mutation
completely abrogated ERa occupancy. Overall, these results
support a distinct role for p53-inducing cellular treatment that
appears related to the specific nature of the cis-element sequences
in FLT1. Furthermore they indicate that ERE2 is an active ER K
site and suggest a contribution of ER proteins on the stability/
recruitment of p53 at the promoter.
ER ligands differentially impact FLT1-T transactivation
The ER activity at FLT1-T [17] is ligand dependent. We
determined if ER ligands differ in their impact on FLT1-T
transactivation. Using luciferase assays, the transiently transfected
MCF7 cells were treated with several compounds chosen for their
established or proposed estrogen-like activity along with doxoru-
bicin. The responses with the pS2/TFF1 ER target promoter were
compared to those on FLT1-T (Figure 6A and 6B). Doses were
chosen that had similar effects with the pS2/TFF1 ER target
promoter. Contrary to the effect on TFF1, genistein, 2-
methoxyestradiol and bisphenol A appeared to be more effective
than 17b-estradiol (E2) in enhancing doxorubicin-induced FLT1-
T transactivation. 2-methoxyestradiol (2Me-OE2) was used based
on a previous report of an agonist effect in MCF7 [44,45]. Other
reports have instead concluded that this molecule is not capable to
engage the ERs [46]. We used different concentration of 2ME-
OE2 and examined the impact on the pS2/TFF1 reporter.
Figure 2. p53 and estrogen receptors cooperate in FLT1-T transactivation in HMEC cells. Cells were transiently co-transfected with the
FLT1-C, FLT1-T or FLT1-T-ere1 reporter constructs along with expression vectors for p53, ERa and/or ERb. Relative luciferase activity was determined
24 hours after transfection. Presented are the average relative light units and the standard errors of three biological repeats.
doi:10.1371/journal.pone.0010236.g002
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tested (1, 10, 100 nM), 2Me-OE2 led to reporter transactivation
only at the 100 nM concentration. This agonist effect was
abolished by the addition of the ICI-182,780 ER antagonist.
Zearalenone had a similar impact relative to E2 on the two
reporters while 2-methoxyextrone (EI) had a little impact on
FLT1-T and nonylphenol was inactive. None of the ligands had
any impact on FLT1-T transactivation in the absence of
doxorubicin treatment confirming our previous results that
FLT1 promoter is not responsive to the ERs alone [17]. The
FLT1-T construct was also not responsive to 5FU (less than two
fold compared with a 13 fold induction by doxorubicin)
(Figure 6B). Consistent with the results presented in Figure 1H,
disruption of the ERE1 site abolished doxo responsiveness in
estrogen depleted medium. Addition of 100 nM E2 or Genistein
did not lead to any induction. The FLT1-C construct was not
responsive. The induction observed after genotoxic treatment was
equivalent with the empty vector (data not shown; see Figure 1).
[17]
p53-activating agents differentially impact the
endogenous FLT1 gene expression
Using real time RT-PCR approach we quantified endogenous
mRNA expression levels of the FLT1 gene after different genotoxic
treatments. The p53 positive HCT116 p53
+/+ and neuroblastoma-
derived GIMEN cell lines were used because they were found to
be heterozygous for the C.T SNP in the FLT1 promoter. The
MCF7 (C/C) cells were used as controls. The relative mRNA
levels for the p53 target gene p21 were measured in comparison
with those of FLT1. The basal levels of FLT1 mRNA varied
Figure 3. The p53-related p73b and p63c proteins do not transactivate the FLT1 promoter constructs in SaOS2 cells. To avoid any
contribution of the endogenous p53 protein, gene reporter assays were performed in a p53-null, osteosarcoma-derived SaOS2 cell line. (A) Cells were
transiently co-transfected with the FLT1-C or FLT1-T reporter constructs along with an overexpression vector for p53, p73b or p63c as well as the pRL-
SV40 control vector, followed by doxorubicin (0.3 mg/ml) or mock treatment, according to the schedule described in Figure 1. Presented are the
average-fold luciferase induction relative to FLT1-C mock treated and the standard errors of three replicates. Statistically significant differences
relating to the impact of p53 expression alone or in combination with doxorubicin treatment are highlighted (*= p,0.01;
‘=p,0.05, t-test). (B) The
PG13 p53 reporter plasmid was used as a control for comparing the transactivation potential of p53, p73b or p63c and the effect of the doxorubicin
treatment.
doi:10.1371/journal.pone.0010236.g003
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nearly undetectable in GIMEN, very low in HCT116, but
significantly higher in MCF7 cells (data not shown). The FLT1
mRNA was strongly induced by doxorubicin in GIMEN and
HCT116, but not in MCF7 cells, while p21 was clearly induced in
all three (Figure 7A). Transfected FLT1-T reporter constructs
were inducible in the MCF7 cells (Figure 1A), demonstrating the
potential for combined p53/ER-mediated regulation. Treatment
of GIMEN with 5FU led to the induction of p21 expression but
FLT1 mRNA levels were not changed, consistent with the results
obtained in the gene reporter assays (Figure 7B). To study at the
endogenous gene level the cooperation between doxorubicin and
E2, mRNA was quantified in GIMEN cells culture in estrogen-
depleted medium (Figure 7C). Combined treatment with doxoru-
bicin and E2 led to a significant increase in FLT1 mRNA
expression compared the effect of doxorubicin alone. On the
Figure 4. Differential effect of doxorubicin and 5-fluorouracil treatment on FLT1-T transactivation. (A) MCF7 cells were seeded into 12-
well plates and transfected either with empty, FLT1-C or FLT1-T plasmids, along with the pRLSV40 control vector. 24 hours after transfection cells
were treated with doxorubicin (0.3 mg/ml) or 5FU (375 mM) or mock treated, as indicated. At 16-hour post-treatment, cells were lysed for the
luciferase assays. The relative averages and standard errors of at least three independent replicates are presented. (B) Western blot analysis of the p53
(DO-1 antibody), p21 (C-19 antibody) and ERa (H-184 antibody) proteins after treatment with doxorubicin and 5FU. 30 ug of total proteins were
loaded in each lane. Actin (C-11 antibody) was used as loading control. All antibodies were obtained from Santa Cruz. The bands above actin are due
to a residual p53 signal caused by incomplete removal of the primary Ab against p53 while re-probing for actin. (C) MCF7 cells cultured in estrogen-
depleted medium for 72 hrs, were seeded into 24-well plates and transfected with empty or pS2/TFF1 reporter vector. 24 hours after transfection
cells were treated with doxorubicin (0.3 mg/ml) or 5FU (375 mM) and/or with the addition of 100 nM E2. At 16-hour post-treatment, cells were lysed
for the luciferase assays. The relative averages and standard errors of at least three independent replicates are presented. E2 led to a significant
induction (*= p,0.01, t-test) of the pS2/TFF1 reporter that was not impacted by doxo or 5FU treatment.
doi:10.1371/journal.pone.0010236.g004
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compared to doxorubicin alone. As an additional control we
conducted real time RT-PCR analysis of HMEC cells that are
homozygous (C/C) for the SNP in the FLT1 promoter. p53 and/
or ERa and/or ERb were ectopically expressed in these cells that
were also treated with ER ligands (estradiol and diethylstilbestrol)
Figure 5. The ERE2 site is important in the recruitment of p53 and ERa on FLT1-T promoter constructs transfected in MCF7 cells. (A)
Schematic drawing of the annealing positions of the PCR primers utilized in the ChIP experiments to probe the individual response elements. (B, top
panels) representative PCR results that evaluate the occupancy of p53 or ERa after mock, doxorubicin and 5FU treatments obtained with primers
specific for the p53 RE, ERE1 and ERE1 region. (B, lower panels) same as in top panel except that the indicated FLT1-T mutant constructs were
transfected. ChIP PCR reactions for p53RE, ERE1 and ERE2 were performed with the single mutant ere1 or the double mutant ere1,2 within the pGL3
based constructs after ChIP with p53 and ERa antibodies, respectively. PCR results obtained with input DNA and with IP material obtained from a
negative control IgG antibody are also shown. (C) Fold change in site occupancy measured using real time PCR. Data are presented following the
same order as in (A). The antibody used for the ChIP experiment was targeted at p53 for the reported analysis at the p53RE site and at ERa for the
analysis at the ERE1 or ERE2 sites. Bars represent the average fold change in occupancy and standard deviations of three technical replicates.
doi:10.1371/journal.pone.0010236.g005
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depleted medium and serum, seeded into 12-well plates and co-transfected with the empty luciferase vector, the pS2/TFF1 ER reporter vector (A) or
FLT1-C, FLT1-T or FLT1-Tere1 constructs (B) along with the pRL-SV40 control vector. Cells were incubated with the various ER ligands at the indicated
concentrations. Where indicated, cells were also treated with doxorubicin (0.3 mg/ml) or 5FU (375 mM). Luciferase assays were performed on total
protein extracts prepared 48 hours post-transfection (16 hours after DNA-damaging treatment, 10 hours after ligand addition). The histograms
represent the average light units and the standard errors of three independent biological replicates. E2=17-b-estradiol; 2-MeO-E2 =2-
methoxyestradiol; EI=2-methoxyestrone.
doi:10.1371/journal.pone.0010236.g006
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FLT1-T reporter constructs (Figure 2), we did not observe any
induction of the endogenous FLT1 gene, confirming that the
combined p53/ER responsiveness requires the T allele and that
the gene is not inducible by ERs alone (Figure S2).
Discussion
We have characterized the in cis interaction between p53 and
estrogen receptors that can result in transcriptional modulation of
the FLT1 promoter containing a p53 responsive SNP in a breast
cancer cell model where estrogen responses might be expected to
be more significant. Specifically, we investigated cis-acting FLT1
promoter features and explored environmental components,
namely genotoxic stress conditions and estrogenic ligand exposure,
resulting in the combined activation of p53 and ERs. Importantly,
we identified a second functional cis-acting ERE K site located
145 nt downstream to the p53 K site in the FLT1 promoter.
Using site-specific mutagenesis, ectopic expression of ERs,
transactivation assays and ChIP studies with the breast cancer-
derived MCF7 cells, the colon cancer-derived HCT116 cells and
the HMEC cells, we confirmed that this ERE2 can participate in
the cooperative interaction between p53 and ERs. The ERE2 can
recruit ERa even when the ERE1 sequence is mutated. Disruption
of both EREs abrogated ER binding and nearly abolished p53
binding to the p53 RE-T region, consistent with the results of the
functional assays. Notably, gene reporter assays, RT-qPCR for the
endogenous gene, Western Blot and ChIP experiments consis-
tently indicated that the nature of the genotoxic-stress resulting in
p53 activation (i.e., doxorubicin vs. 5-fluorouracil) dictated the
engagement and the function of p53 at the FLT1 promoter.
The exact mechanisms that differentiate the impact of
doxorubicin and 5FU on FLT1, including the involvement of
other cis-acting sequences, remains to be explored and might be
related to distinct p53 post-translational modifications induced by
the signaling pathways activated upon treatment with these
genotoxic drugs [41,47]. Alternatively, the mechanisms may relate
to the availability of cofactors or even the combined activation of
Figure 7. Exposure-dependent, differential induction of the endogenous FLT1 and p21 genes. The relative expressions of FLT1 (gray
bars) and p53 target gene p21 (black bars) in mock, doxorubicin or 5FU treated cells were compared using an RT-PCR approach in real time. GIMEN
(neuroblastoma-derived) and HCT116 (colon adenocarcinoma) are heterozygous (CT) for the promoter SNP at the FLT1 promoter while MCF7 cells are
homozygous for the p53 nonresponsive SNP allele (CC). The HCT116 p53
2/2 derivative cell line was used as control for p53-independent effects.
GAPDH or B2M expression levels served as normalization controls. Histograms described the average fold-induction relative to the housekeeping
gene, calculated using the DCt method. Error bars correspond to standard errors of at least three replicates. (A) Comparison between GIMEN, HCT116
and MCF7 cells. (B) Differential impact of doxorubicin and 5FU on FLT1 expression in GIMEN cells. Since the basal levels of FLT1 expression were very
low (Ct$30), the fold of induction may appear somewhat exaggerated. C) Impact of doxorubicin and/or E2 on FLT1 and p21 mRNA expression in
GIMEN cells culture in estrogen-depleted medium. The increase in FLT1 mRNA expression by combined doxorubicin and E2 treatment appeared to
be statistically significant (
‘=p,0.05, t-test).
doi:10.1371/journal.pone.0010236.g007
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previous studies designed to interpret stress-dependent differences
in the global p53 transcriptional network [20,48,49], or may be a
feature that is unique to a K site noncanonical p53 target. Overall,
our results indicate that the noncanonical nature of the cis-acting
elements that enables p53 and ER cooperation at the FLT1
promoter provides higher potential for adaptive tuning of the
transcriptional responses compared to highly responsive p53 target
genes, such as p21, and may suggest differences in responsiveness
to altered function p53 mutants [27].
In a recent study [26] we examined p53 transactivation
potential using various permutations of K site RE sequences,
confirming that p53 transactivation from this type of noncanonical
regulatory sequence is affected by specific sequence features of the
RE, similar to what is observed for full-site (tetrameric) canonical
REs. The FLT1 K site (GGACATGCTC) ranked low in the
comparison of the transactivation potential of K site REs, despite
the presence of the CATG in the core sequence. In fact, we noted
an unexpected negative impact on transactivation that was
associated with the ‘‘CT’’ sequence context in the RE. When a
transcriptionally optimized K site was used, there was a ,20 fold
higher transactivation potential compared to the FLT1 RE [26]. It
will be important to determine the effect of varying the intrinsic
transactivation potential of a p53 RE on the combinatorial
interaction between p53 and the estrogen receptor.
In this work, we also explored the contribution of the p53-
related p63 and p73 transcription factors in the transactivation of
FLT1 and the cooperation with ER, drawing upon recent reports
on the differential DNA binding specificity between p53 and p63
[50,51]. The reported preference of p63 for an ‘‘S’’ base (i.e. aCo r
G) instead of a ‘‘W’’ in the core p53 RE (CWWG) suggested to us
the intriguing possibility that p63 and p73 may exhibit preferential
activity towards the FLT1-C allele. However, experiments in
SaOS2 cells indicated that neither p63 nor p73 play a role in
FLT1 transactivation, regardless of SNP status. This lack of
activity could be related to a generally lower DNA binding/
transactivation potential of p63 and p73 towards weak p53 REs,
consistent with previous observations [52], or to the fact that the
cooperativity with the ERs is achieved by specific cofactors whose
interaction with the p53 family of transcription factors is restricted
to the p53 protein.
In this study we confirmed that the effect of ER on FLT1
transactivation requires at least one cis-acting ERE and is
dependent on the interaction with specific ligands. ERa and
ERb appeared to act similarly in the in cis interaction with p53
[17], although we noted a stronger impact of ERb in HCT116
cells. The disruption of a single ERE did not impact doxorubicin
responsiveness in the MCF7 cells (Figure 1A) and had a small
effect in HCT116 p53+/+ or HMEC cells when ERa and
especially ERb were overexpressed (Figure 1C, D and Figure 2).
Surprisingly, when MCF7 cells were cultured in estrogen-reduced
medium supplemented with 10 nM E2, disruption of either ERE1
or ERE2 resulted in loss of doxorubicin responsiveness (Figure 1H).
Consistent with this, previous experiments developed in the
osteosarcoma derived U2OS and SaOS2 cells, showed that
disruption of a single ERE (ere1) impaired p53-dependent
transactivation even with ectopic expression of ERa or ERb
[17]. ChIP assays in SaOS2 showed that ERE1 disruption did not
impair p53 binding at the p53 RE but seemed to affect ER binding
[17], based on the lack of recruitment of the TRA220 subunit of
the mediator complex that can bind to ERs [53]. Using MCF7
cells, in this study we have confirmed that p53 binding is required
for ER binding, but have also revealed that ERa occupancy can
stabilize p53 binding at FLT1-T given that disruption of both
EREs strongly reduced p53 occupancy. Taken collectively, our
results suggest that, besides ER protein levels, other factors can
modulate the p53/ER cooperation at the FLT1 proximal
promoter in the context of a doxorubicin response. This is
consistent with the genotoxic stress-dependency previously de-
scribed and the cell type specific effects.
Given that only K site EREs are present in the FLT1 promoter
and that p53 is required for ER-dependent transcriptional
stimulation, we evaluated the impact of different ER ligands on
FLT1-T transactivation and compared responses with a typical
estrogen-responsive promoter, derived from the pS2/TFF1 gene
using MCF7 cells cultured in estrogen-reduced conditions.
Previous studies revealed ligand dependencies in target specificity
[30]. Included in our test were the dietary phytoestrogens genistein
and zearalenone and the industrial estrogens bisphenol A and
nonylphenol [30]. We also tested 2-methoxyestradiol, that was
shown to exhibit anti-angiogenic activity and could have agonist
activity on ERs at high concentrations [45] and 2-methoxyestrone
another estrogen metabolite that had been investigated for anti-
proliferative properties [44]. Ligand doses were chosen based on
the literature [30] and on assays with the pS2/TFF1construct
(Figure 6A). While exploratory in nature, our results suggest a
differential impact of the various ligands in the FLT1-T promoter
context, as compared to pS2/TFF1. In particular, genistein and
bisphenol A appeared more active than 17b–estradiol, while
nonylphenol and 2-methoxyestrone were not active (Figure 6B). It
will be interesting to address the relative impact in the FLT1
promoter motif where the K site is replaced by a full-site. Previous
studies compared different ER ligands using reporter constructs
with different ERE sequences [30,31]. While promoter specific
effects were reported for the impact of specific ligands or the
relative contribution of ERa and ERb, the quantitative differences
among the impacts of genistein, bisphenol A and nonylphenol
relative to 17b–estradiol were smaller compared to what is seen
with the FLT1-T promoter construct.
The value of p53 mutant status as an independent tumor
prognostic marker was found in large cohorts of sporadic breast
cancers [54]. Recently, immunohistochemical and molecular
analyses have identified different breast cancer subtypes [55,56].
Among these, the basal-like tumors, clinically very aggressive, are
defined by the lack of expression of ER, Progesterone Receptor
(PR) as well as epidermal growth factor receptor 2 (HER2) and by
a high frequency of p53 mutations. Instead the luminal subtypes
are p53 wild type and ER/PR positive and associated with a more
favorable prognosis. However, luminal B subtype tumors that are
classified based on the reduction or loss of ER/PR expression, in
some cases associated with gain of HER2 expression, have a
significantly worse outcome (54). Direct molecular links between
ER expression, p53 WT or mutant status, and disease outcome
still need to be fully established. The transcriptional cooperation
we uncovered at FLT1 should be evaluated in this context.
The transcriptional circuit provided by the C.T SNP at the
FLT1 promoter, appears to bring an additional angiogenesis gene
into the p53 transcriptional network. Previous studies have linked
p53 to the modulation of angiogenesis both through transcrip-
tional repression of VEGF [57] and induction of the metallopro-
teinase MMP2 [58], maspin [59] and PAI [60]. p53 was also
shown to be directly involved in the degradation of collagen,
resulting in the production of antiangiogenic peptides [61]. Other
studies have linked p53 to the control of the migratory potential of
various cell types, including macrophages [62,63]. Importantly,
ER proteins have also been directly linked to the up-regulation of
VEGF [64]. Recent results in the literature have highlighted the
potential key role of membrane-bound FLT1 in pathological
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[3]. In particular, FLT1 is the main receptor for VEGFB and
PlGF induced signaling and is over-expressed in several cancer
cells [3]. In the case of neuroblastoma, FLT1 expression was
linked to chemoresistance, especially in the context of low oxygen
tension [8]. Furthermore, bone-marrow-derived FLT1-positive
cells are required for the initial formation of pre-metastatic niches
in a model of lung tissue metastasis in nude mice [16]. The
biological consequences of the inclusion of FLT1 among the p53
target genes are, however, difficult to predict and await specific
investigations. Furthermore, the complexity of the FLT1 regula-
tion is enhanced by the synthesis of a soluble form of the receptor
(sFLT1), deriving from alternative splicing of the FLT1 primary
transcript that can exert opposite functions compared to the
membrane-bound, full-length form (mFLT1) [65–67].
Overall, our results have identified cis- and trans- factors
resulting in the integration of signaling responses that coordinate
allele-specific FLT1 transactivation by p53 and estrogen receptors.
This study provides further evidence for the functional role of p53
K site response elements in modulating p53 transcriptional
responses resulting in concerted regulation of gene targets through
cooperation with other sequence-specific TFs. This type of
functional interaction could be relevant for the modulation of
many yet undiscovered gene targets and contribute to the
regulation of p53 transactivation selectivity, tailoring responses
to specific cellular stress conditions. In a related study, we have
examined the influence of the FLT1 promoter motif on the p53/
ER transcriptional cooperation with various p53 response element
sequences—both canonical and noncanonical placed within the
FLT1 promoter context--. This study (in press) has revealed the
generality of the in cis interaction between p53 and ER;
furthermore, we showed that the enhanced transactivation can
extend to cancer-associated p53 mutations.
Materials and Methods
Cell lines and culture conditions
The human breast adenocarcinoma-derived MCF7 cell line
(p53 wild type, positive for both ERa and ERb) was obtained from
the InterLab Cell Line Collection bank, ICLC (Genoa, Italy). The
metastatic neuroblastoma GIMEN cells (p53 wild type) were
obtained from GP Tonini (National Institute for Cancer Research,
IST, Genoa, Italy), while the colon adenocarcinoma HCT116
(p53
+/+) cell line and its p53
2/2 derivative and the osteosarcoma-
derived SaOS2 cells (p53-null) were a gift from B. Vogelstein (The
Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland,
USA). Human endothelial cells from dermal microvessels were
derived in the Schoenfelder lab and cultured as previously
described. Cells were normally maintained in DMEM or RPMI
supplemented with 10% FCS and antibiotics (100 units/ml
penicillin plus 100 mg/ml streptomycin). GIMEN medium was
supplemented with +1% non-essential amino acids. For the
experiments with the ER ligands, cells were instead maintained
in estrogen-depleted medium consisting of DMEM or RPMI
without Phenol Red (Euroclone, Celbio, Milan, Italy) supple-
mented with 10% Charcoal-Dextran treated FCS (Hyclone,
Celbio, Milan, Italy).
Plasmids
Vectors carrying 1 Kb fragments derived from the human
FLT1 proximal promoter were cloned in pGL3 promoter
backbone (Promega, Milan, Italy) as described previously [17].
FLT1-T refers to the fragment containing the rare C.T SNP.
FLT1-C is an equivalent fragment containing the common C
allele. Site-directed mutagenesis (Stratagene, Milan, Italy) or a
two-round, PCR-based, site-specific mutagenesis approach were
performed to mutate the putative Estrogen Receptor Response
Elements (EREs) within the FLT1-T promoter construct. The
sequences of the primers used for site-specific mutagenesis are
presented in Table S1. Mammalian expression plasmids harboring
p63 and p73 cDNAs were a gift from G. Blandino (Regina Elena
Cancer Institute, Rome, Italy) and M. Levrero (University of
Rome ‘‘La Sapienza’’, Rome, Italy). The PG13 p53 reporter
plasmid (obtained from B. Vogelstein, The Johns Hopkins Kimmel
Cancer Center, Baltimore, Maryland, USA) [39], was used as a
transactivation control. The pS2/TFF1 reporter vector contains
1.3 kb of the proximal promoter of the estrogen-responsive gene
TFF1 cloned in the pGL3-basic backbone [68]. All mammalian
constructs were extracted from XL1blue E. coli cells using QIAex
endofree maxi prep kit, according to the manufacturer’s protocol
(QIAGEN, Milan, Italy).
Luciferase Assays in Transient Transfection Experiments
For each cell line 1-2.5610
5 or 4-8610
4 cells were seeded
respectively in 12-well plates or 24- well 24 h before the
transfection. Cells were transfected using FuGENE 6 (Roche,
Milan, Italy) according to manufacturer’s instructions at ,80%
cell confluence. For both types of plates, 300 ng of the pGL3-
FLT1 reporter plasmids or pGL3-TFF1/pS2 ER reporter or
PG13 p53 reporter were used. When appropriate, 100 ng of the
expression vector for ERa/ERb or for p53 family members (or a
control empty vector) were included. All transfections were
normalized for efficiency using 50 ng of the pRLSV40 plasmid,
harboring the luciferase gene from Renilla reniformis controlled by a
constitutive promoter (Promega, Milan, Italy). The total plasmid
DNA amount per well was kept constant at 450 ng adding the
empty vector pCMV-NeoBam, when appropriate. 24 h after
transfection doxorubicin or 5-fluorouracil (5FU) were added in the
medium at the indicated doses. In all experiments, cells were
harvested 16 h after drug treatment and luciferase assays were
conducted as described previously [68].
Western Blot Analysis
Cell extracts were quantified using the BCA protein assay kit
and BSA as a reference standard (Pierce, Celbio, Milan, Italy), and
equal amount of proteins were resolved on 7.5% BisTris
Acrilamide gels, and transferred to Nitrocellulose or PVDF
membranes (GE Healthcare, Milan, Italy) using a Biorad
MiniProtean apparatus (Biorad, Milan, Italy). After blotting the
membranes were probed with monoclonal (p53 specific: pAb1801
and DO-1, Santa Cruz Biotechnology, Milan, Italy) or polyclonal
antibodies (p53: CM-1, Novocastra, Milan, Italy; p21: C-19; ERa:
H-184, Santa Cruz Biotechnology, Milan, Italy). The quality as
well as the equal loading and transfer of protein blots were
determined by Ponceau S staining or using a monoclonal antibody
against b-actin (C-11 Santa Cruz Biotechnology, Milan, Italy).
The relative Molecular mass (Mr) values of the immunoreactive
bands were determined by using molecular weight markers
(Fermentas, Milan, Italy). After washing, blots were incubated
with the appropriate IgG- horseradish peroxidase conjugated
secondary antibody (Santa Cruz Biotechnology, Milan, Italy), and
immune complexes were visualized by using ECL plus reagent
(GE Healthcare, Milan, Italy).
Chromatin Immunoprecipitation (ChIP) Assays
ChIP assays were done as previously described [17] using the
ChIPkit(UpstateBiotechnology,Millipore,LakePlacid,NY,USA).
Briefly, cells were plated onto 150-mm dishes. After 24 h of
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formaldehyde for 10 min at 37uC and then treated with 125 mM
glycine for 5 min. Samples were processed following the manufac-
turer’sinstructions.Celllysateswerethen sonicatedusingconditions
that enabled us to evaluate the distinct contribution of ERE1 and
ERE2 which are less then 400 nt distant. The sonication was done
using a Misonix 3000 instrument equipped with a deep cup horn.
Samplesweresonicatedusing six cyclesof20secondpulsesat power
setting 8 with a 40 seconds pause in-between. One microgram of
ERa (H-184, Santa Cruz, Biotechnology) and DO-7 p53-specific
monoclonal antibodies (BD Biosciences Pharmingen, San Jose, CA,
USA) were used per ChIP assay. As a negative control we used
mouse or rabbit Ig (Santa Cruz Biotechnology). PCR amplifications
wereperformedonimmunoprecipitated chromatinusing primersto
amplify specificregions in the FLT1 promoter (Table S2). The PCR
cycles were as follows: an initial 10 min Taq Gold polymerase at
95uC followed by 40 cycles of 95uC for 15 s and 60uC for 1 min.
The PCR products were then run on a 1.8% agarose gel and
quantified with IMAGEQUANT V5.1 (Molecular Dynamics-GE,
Piscataway, NJ, USA). Alternatively, qPCR in real time was used to
quantify the fold change insite occupancy.qPCR reaction wasdone
with 2 mL of each sample and using the Power SYBRH Green PCR
Master Mix (Applied Biosystems, Foster City, CA, USA) following
themanufacturer’srecomendation.Todeterminethefold changein
site occupancy the SuperArray ChIP-qPCR Data Analysis tool was
used (SA Biosciences, Frederick, MD, USA).
Real Time PCR
For the mRNA expression analyses, MCF7, HCT116 and
GIMEN cell lines were seeded onto 100 mm Petri dishes and
allowed to reach 70–80% of confluence before treating with
different drugs as described in the figures. At least 16 hours after
treatment cells were harvested and washed once with PBS. Instead,
HMEC cells were cultured in estrogen-depleted medium, transient-
ly transfected with p53 and/or ERs expression vectors and treated
with pro- and anti- estrogenic compounds at different concentra-
tions. Total RNA was extracted using the RNeasy Kit (Qiagen,
Milan, Italy) according to the manufacturer’s instructions. For real-
time quantitative PCR, cDNA was generated from 1 mg of RNA by
using the AffinityScript cDNA Synthesis Kit (Stratagene, Milan,
Italy). Real-time PCR was performed on a RotorGene 3000
thermal cycler (Corbett Life Science, Ancona, Italy) using the
5PRIME MasterMix (Eppendorf, Milan, Italy). Primers and
TaqMan probes are presented in Table S2. Relative mRNA
quantification was obtained using the DCt method, where the
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), the b2Mi-
croglobulin (B2M) or the b-actin genes served as internal control.
Supporting Information
Figure S1 Impact of doxorubicin and 5FU on p53 and ER
occupancy at target sites. (A): Doxorubicin and 5FU treatment
result in a similar increase of p53 occupancy at the p21 promoter.
(B) Doxorubicin and 5FU treatment showed a similar negative
effect on ERa occupancy at the TFF1 promoter. Shown are
representative PCR results obtained using template DNA retrieved
from ChIP experiment conducted in MCF7 cells with the
indicated primary antibodies and primers specific for the p53
RE and ERE1 containing regions of the target promoters. The
effect of doxorubicin and 5FU were compared. In addition to a
p53 specific Ab (DO1) and an ERa Ab (H-184 Santa Cruz) the
IgG Ab was used as negative control. PCR of input DNA is also
shown. (C) Fold change in site occupancy measured using real
time PCR. Data are presented following the same order as in
panel A. The antibody used for the ChIP experiment was targeted
at p53 for the p21 promoter site and at ERa for pS2/TFF1
promoter site.
Found at: doi:10.1371/journal.pone.0010236.s001 (0.21 MB
DOC)
Figure S2 Quantification of FLT1 mRNA in response to p53,
ER overexpression in HMEC cells. (A) Cells were transfected with
expression vectors for p53, ERa or ERb as indicated. (B) Cells co-
transfected with p53, ERa and ERb were also treated 24 hours
after transfection by estrogen ligands (Estradiol, E2; Diethylstil-
bestrol, DES) at the indicated concentrations (M). When indicated,
treatment included a 100-fold excess of the ER antagonist ICI
182,780. For both panels, histograms represent the average fold of
induction relative to the beta-actin housekeeping gene, calculated
using the DCt method. Error bars present the standard errors of at
least three replicates.
Found at: doi:10.1371/journal.pone.0010236.s002 (0.09 MB
DOC)
Table S1 Primers for 2-round PCR mutagenesis of 1 Kb FLT1-
T constructs and description of method.
Found at: doi:10.1371/journal.pone.0010236.s003 (0.05 MB
DOC)
Table S2 List of the primers (A), the probes (B) used in the Real
Time PCR experiments and (C) the primers used in ChIP
experiments.
Found at: doi:10.1371/journal.pone.0010236.s004 (0.05 MB
DOC)
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